HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Shareholder Value Destruction" following Tiger scandal

This article was originally published in The Rose Sheet

Executive Summary

New report from the University of California, Davis, focuses not on Tiger Woods' future earning potential, but instead "estimate[s] losses that may be larger, more widely felt, and more immediate: those incurred by shareholders of the firms paying Mr. Woods to endorse their products." Professors Christopher R. Knittel and Victor Stango figure that shareholders of companies that sponsored the pro golfer lost $5 bil.-$12 bil. in wealth in the two weeks between Woods' car accident and announced leave-taking from golf. Losses were measured "relative to both the entire stock market and a set of competitor firms," they note. Woods' top five sponsors - P&G's Gillette, Accenture, Nike, Electronic Arts and Gatorade - each lost 2%-3% of their aggregate market value after the car accident, the authors assert. Gillette announced Dec. 12 it would "limit" Woods' role in marketing and promotional efforts (1"The Rose Sheet" Dec. 21, 2009)

You may also be interested in...



Gillette Downsizes Tiger Woods' Marketing Role

Procter & Gamble/Gillette says it will curtail its use of golf superstar Tiger Woods in promotions

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.

Investors Go Berserk For Viking, Putting It Top Of Q1 Winners

The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel